Four reasons why open pharma might succeed – During the last decade or so (coincident with the development of open access journal PLoS One, as it happens), the paradigm of “open”, as in open innovation, has changed the way R&D; is organised and run in countless high-technology firms. However, the open innovation model has to be adapted and modified to fit specific areas. French researchers have now surveyed managers across the UK’s biopharmaceutical sector at the small-medium enterprise (SME) level to identify what needs to be improved to open innovation still further.
This site uses some cookies to make things work properly. If you continue, then we assume you're happy with that.OK